<DOC>
	<DOCNO>NCT00501124</DOCNO>
	<brief_summary>A randomize , parallel , multicenter , active-controlled 48 week treatment period . Patients randomize receive clevudine alone 48 week clevudine 24 week follow 24 week clevudine addition monthly HBV vaccination.The purpose study investigate efficacy combination clevudine HBV vaccine clevudine alone patient chronic hepatitis B infection .</brief_summary>
	<brief_title>Safety Efficacy Study Clevudine Compared With Clevudine Vaccine Patient With HBeAg ( + ) Chronic HBV</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Clevudine</mesh_term>
	<criteria>1 . Patient 18 60 2 . Patient HBV DNA positive DNA level ≥ 5 x 10 ( 6 ) copies/mL within 30 day baseline . 3 . Patient document HBsAg positive &gt; 6 month . Patient HBeAg positive . 4 . Patient ALT level range ≥2 x ULN/L least 2 consecutive visit , least one month apart bilirubin level less 2.0 mg/dL , prothrombin time le 1.7 ( INR ) , serum albumin level least 3.5 g/dL . 5 . Women childbearing potential must negative urine ( βHCG ) pregnancy test take within 14 day start therapy . 6 . Patient able give write informed consent prior study start comply study requirement . 1 . Patient currently receive antiviral , immunomodulatory , cytotoxic corticosteroid therapy . 2 . Patients previously treat interferon , lamivudine , adefovir , entecavir , telbivudine investigational nucleoside HBV infection . 3 . Patient history ascites , variceal hemorrhage hepatic encephalopathy . 4 . Patient coinfected HCV , HDV HIV . 5 . Patient clinical evidence decompensated liver disease HCC 6 . ANA &gt; 1:160 positive antismooth muscle antibody evidence autoimmune hepatitis 7 . Patient pregnant breastfeeding . 8 . Patient unwilling use `` effective '' method contraception study 3 month use study drug cease . 9 . Patient clinically relevant history abuse alcohol drug . 10 . Patient significant immunocompromised , gastrointestinal , renal , hematological , psychiatric , bronchopulmonary , biliary disease exclude asymptomatic GB stone , neurological , cardiac , oncologic allergic disease medical illness investigator 's opinion might interfere therapy . The patient benign tumor , exclude judge investigator continuation study would interfere tumor . 11 . Patient creatinine clearance le 60mL/min estimate follow formula : ( 140age year ) ( body weight [ kg ] ) / ( 72 ) ( serum creatinine [ mg/dL ] ) [ Note : multiply estimate 0.85 woman ]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>